Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203-1738, USA.
Menopause. 2009 Nov-Dec;16(6):1205-12. doi: 10.1097/gme.0b013e3181aac32b.
The aim of this study was to estimate the prevalence of menopausal symptoms in relation to treatment modalities in Asian women treated for breast cancer.
A population-based cohort of 5,023 Chinese women aged 25 to 70 years with primary stage 0 to III breast cancer was identified from a population-based tumor registry and enrolled in the study approximately 6 months after diagnosis. Participants were asked about the occurrence of specific menopausal symptoms. Associations between these symptoms and breast cancer treatments were evaluated by stratified, multivariate logistic regression.
Among women with a recent diagnosis of breast cancer, 67.2% of premenopausal women and 46.3% of postmenopausal women experienced at least one menopausal symptom, namely, hot flashes, night sweats, and/or vaginal dryness. Symptom prevalence among postmenopausal women decreased progressively with age at diagnosis (63.3% for women aged 51-55 y, 51.5% for women aged 56-60 y, and 34.4% for women aged >65 y; P < 0.01). Overall, the highest prevalence of most symptoms occurred in women aged 46 to 55 years (P < 0.01). Chemotherapy was positively associated with the occurrence of any symptom and with each individual symptom, mainly in premenopausal women (adjusted odds ratio [OR] range, 2.2-3.3; P < 0.05 for all). Tamoxifen use and immunotherapy were associated with having any symptom and with each individual symptom, regardless of menopause status (adjusted OR range, 1.5-1.8 and 1.3-1.5, respectively; P < 0.05 for all). Women treated before menopause were at particularly high risk of experiencing two or more symptoms after chemotherapy (OR, 1.77; 95% CI, 1.54-4.98; P interaction = 0.05) compared with postmenopausal women.
Menopausal symptoms are prevalent among Chinese women recently treated for primary breast cancer. These symptoms are associated with age and menopause status at the time of diagnosis, as well as with the type of treatment received.
本研究旨在评估与亚洲女性乳腺癌治疗方式相关的绝经症状发生率。
从人群为基础的肿瘤登记处确定了 5023 名年龄在 25 至 70 岁之间的中国女性，她们患有原发性 0 至 III 期乳腺癌，大约在诊断后 6 个月入组本研究。参与者被问到特定的绝经症状发生情况。通过分层、多变量逻辑回归评估这些症状与乳腺癌治疗之间的关系。
在最近被诊断患有乳腺癌的女性中，67.2%的绝经前女性和 46.3%的绝经后女性经历了至少一种绝经症状，即热潮、盗汗和/或阴道干燥。随着诊断时年龄的增长，绝经后女性的症状发生率逐渐下降（51-55 岁女性为 63.3%，56-60 岁女性为 51.5%，>65 岁女性为 34.4%；P < 0.01）。总体而言，大多数症状的最高发生率出现在 46 至 55 岁的女性中（P < 0.01）。化疗与任何症状的发生以及每个单独的症状均呈正相关，主要见于绝经前女性（调整后的优势比[OR]范围，2.2-3.3；所有 P < 0.05）。他莫昔芬使用和免疫治疗与出现任何症状以及每个单独的症状均相关，无论绝经状态如何（调整后的 OR 范围，1.5-1.8 和 1.3-1.5；所有 P < 0.05）。在绝经前接受治疗的女性在化疗后经历两个或更多症状的风险特别高（OR，1.77；95%CI，1.54-4.98；P 交互=0.05），与绝经后女性相比。
在中国最近接受原发性乳腺癌治疗的女性中，绝经症状普遍存在。这些症状与诊断时的年龄和绝经状态以及所接受的治疗类型相关。
